Platinum Excellence Biotechnology

Platinum Excellence Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of next-generation T-cell receptor engineered T-cell (TCR-T) therapies. The company focuses on addressing unmet medical needs in oncology, particularly for solid tumors such as hepatocellular carcinoma. Its lead program, BOLI-001, is an autologous TCR-T cell therapy targeting Alpha-fetoprotein (AFP) for the treatment of advanced liver cancer. Platinum Excellence leverages a proprietary technology platform to identify high-affinity TCRs and optimize cell manufacturing processes to enhance the efficacy and safety of adoptive cell transfers.